2024 Department of Medicine Grand Rounds | Endemic Mycoses
Most of the medical staff at our hospital is geared towards cancer care and are unlikely to be aware of Endemic fungal infections (e.g., coccidioides, histoplasma, blastomycosis). As such, they often they don’t think of these infections and pursue cancer diagnosis, subjecting patients to procedures even before doing simple blood tests that identify the diagnosis. Example, when a patient comes to City of Hope for evaluation of lung mass, the oncologist or surgeon proceed with biopsy of the lesion, only to identify these infections (and no cancer). The gap is due to the fact that infection is NOT in their differential diagnosis.
Endemic fungal infections are on the rise in our communities, especially with increasing pool of immunocompromised patients and changing environmental conditions (climate/ construction, etc.). Most of the medical community (except infectious disease physicians and public) are mostly not aware of this condition - probably except Valley fever in California and Arizona. It is imperative that all of the medical staff is provided with up-to-date knowledge on these infections. Having this illness in the differential diagnosis in immunocompromised patients, will allow for timely diagnostic evaluation and management for the health of the patient.
Target Audience
All physicians and advanced practice providers (APPs).
Learning Objectives
- Demonstrate knowledge on the epidemiology of endemic mycosis.
- Examine the exposure history, putting some patients at high risk for this infection.
- Integrate this infection into the differential diagnosis in an appropriate setting.
- Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
Virtual Meeting- Zoom
George Thompson, MD, FIDSA, FECMM Professor of Medicine, UC Davis Medical Center
Presenter: Dr. Thompson has indicated the following relevant financial relationships: Grant/Research Support from Astellas, Basilea, Cidara, GSK, Melinta, Mundipharma, and Pfizer.
Planner: Sanjeet Dadwal, MD has indicated the following relevant financial relationships: Consultant for Karius; Grant/Research Support from F2G, and Pfizer/Amplyx Pharmaceuticals.
The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.
CME Committee/Reviewer no relevant financial relationships: Daneng Li, MD
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this 2024 Department of Medicine Grand Rounds | Endemic Mycoses for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 1.00 Attendance